Foundayo, an oral medication manufactured by Eli Lilly and known generically as orforglipron, became available in UK pharmacies following regulatory clearance. The Medicines and Healthcare products Regulatory Agency approved the drug earlier in the month, making the United Kingdom the first European nation to authorize its use.
The medication is indicated for individuals with a body mass index of 30 or higher, as well as those with a BMI between 27 and 30 who have at least one weight-related health condition. It may also be prescribed to enhance blood sugar control in patients with inadequately managed type 2 diabetes. The once-daily oral formulation can be taken at any time without food or water requirements.
Initially, the pill will be accessible through private prescription channels. Eli Lilly stated it is collaborating with the National Institute for Health and Care Excellence regarding an evaluation of Foundayo that could lead to inclusion within the National Health Service in England. The pharmaceutical firm had previously secured approval for another weight-loss tablet in June.
Industry representatives noted that the tablet formulation addresses treatment options for patients unable or unwilling to use injectable therapies. However, pharmacists raised concerns regarding the proliferation of counterfeit, unlicensed, or fake versions of GLP-1 medications. The MHRA previously seized £250,000-worth of unlicensed weight-loss pens and related ingredients from a facility in Northampton, and Eli Lilly has pursued legal action against suppliers allegedly operating in an illegal market for its products. Patients are advised to obtain weight-loss treatments exclusively through authorized and regulated pharmacy channels.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI